- Home
- About
- Guidelines
- HIV Clinical Guidelines: Adult and Adolescent ARV
- HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections
- HIV Clinical Guidelines: Pediatric ARV
- HIV Clinical Guidelines: Pediatric Opportunistic Infections
- Perinatal HIV Clinical Guidelines
- Guidelines for Caring for Persons with HIV in Disaster Areas
- Guidance for COVID-19 and People with HIV
- Archived Guidelines
- Drug Database
- 1 (1 total)
- A (14 total)
- B (3 total)
- C (10 total)
- D (10 total)
- E (17 total)
- F (15 total)
- Famciclovir
- Fidaxomicin
- FluLaval Quadrivalent
- Fluad Quadrivalent
- Fluarix Quadrivalent
- Flublok Quadrivalent Northern Hemisphere
- Flucelvax Quadrivalent
- Fluconazole
- Flucytosine
- Fluzone High-Dose Quadrivalent Northern Hemisphere
- Fluzone Quadrivalent Northern Hemisphere
- Fosamprenavir
- Foscarnet Sodium
- Fostemsavir
- Fuzeon
- G (6 total)
- H (5 total)
- I (8 total)
- J (2 total)
- K (1 total)
- L (8 total)
- M (5 total)
- N (3 total)
- O (1 total)
- P (18 total)
- Panobinostat
- Peginterferon Alfa-2a (HBV, HCV)
- Peginterferon Alfa-2a (HIV)
- Peginterferon Alfa-2b (HIV)
- Penicillin G (Potassium or Sodium)
- Penicillin G Benzathine
- Pifeltro
- Pneumococcal Conjugate Vaccines (15-Valent and 20-Valent)
- Pneumococcal Vaccine, Polyvalent
- Pneumovax 23
- Podofilox
- Prevnar 20
- Prezcobix
- Prezista
- Primaquine Phosphate
- Pyrazinamide
- Pyridostigmine
- Pyrimethamine
- R (13 total)
- S (17 total)
- T (14 total)
- V (15 total)
- Z (4 total)
- Other (1 total)
- Glossary
- AIDS Case Definition
- AIDS-Defining Condition
- Acquired Immunity
- Acquired Immunodeficiency Syndrome (AIDS)
- Active Immunity
- Acute HIV Infection
- Acute Retinal Necrosis (ARN)
- Adherence
- Analytical Treatment Interruption (ATI)
- Antacid(s)
- Antepartum
- Approved Drug
- Area Under the Curve (AUC)
- Assembly
- Asymptomatic HIV Infection
- Attachment
- Backbone
- Binding
- Boosting
- Bronchitis
- Budding
- C-C Chemokine Receptor 5
- C-X-C Chemokine Receptor 4
- CCR5
- CCR5 Antagonist
- CCR5 Inhibitor
- CD4 Receptor
- CXCR4
- CYP3A Inhibitors
- Capsid
- Capsid Inhibitor(s)
- Chronic HIV Infection
- Cisgender
- Clinical Hold
- Clinical Latency
- Clinical Trial
- Cmax
- Cmin
- Cohort
- Community-Acquired Pneumonia (CAP)
- Concordant Couple
- Coreceptor
- Cysteine-Cysteine Chemokine Receptor 5
- Desiccant
- Discordant Couple
- Dosage Form
- Drug Formulation
- Drug Interaction
- Drug-Drug Interaction
- Dual-Tropic Virus
- Empiric Therapy
- Env
- Envelope
- Epstein-Barr Virus (EBV)
- Fixed-Dose Combination (FDC)
- Food and Drug Administration (FDA)
- Formulation
- Functional Monotherapy
- Fusin
- Fusion
- Fusion Inhibitor
- Gag
- Gender-Affirming Hormone Therapy (GHT)
- Genetic Engineering
- HIV Care Continuum
- HIV Continuum of Care
- HIV Progression
- HIV Treatment Cascade
- HIV Viral Core
- HIV Viral Envelope
- Half-Life (t½)
- Hepatitis A Virus Infection (HAV)
- Herpes Simplex Virus (HSV)
- Human Immunodeficiency Virus (HIV)
- Immune System
- Immunity
- Implant
- In Vitro
- In Vivo
- Integrase
- News
- Resources
- Contact Us
- Sponsors
- Nondiscrimination Notice
- Disclaimers
- Accessibility
- Sitemap